Evaluation of vancomycin use in a large university-affiliated hospital in eastern france in 1999

Pharmacy World and Science

Volumn 23, Issue 3, 2001, Pages 93-97

  Floret, N ^a   Thouverez, M ^a   Talon, D ^a   Thalamy, B ^a   Estavoyer, J M ^a  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

Author keywords

Appropriate use; Empirical therapy; Glycopeptide resistance; Hospital pharmacy; Specific therapy; Vancomycin

Indexed keywords

VANCOMYCIN;

ANTIBIOTIC PROPHYLAXIS; ARTICLE; DRUG INDICATION; DRUG UTILIZATION; EMPIRICISM; FRANCE; HOSPITAL INFECTION; HOSPITAL PATIENT; HOSPITAL PHARMACY; INCIDENCE; INFECTION; PHARMACOEPIDEMIOLOGY; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; UNITED STATES; UNIVERSITY HOSPITAL;

ANTI-BACTERIAL AGENTS; DRUG UTILIZATION REVIEW; FRANCE; HOSPITALS, UNIVERSITY; HUMANS; RETROSPECTIVE STUDIES; VANCOMYCIN;

EID: 0034963602     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011269131048     Document Type: Article

References (32)

1. Nosocomial enterococci resistant to vancomycin - United States, 1989-1993
2. Vancomycin use in a hospital with vancomycin restriction
3. Enterococci resistant to multiple antimicrobial agents, including vancomycin. Establishment of endemicity in a university medical center
4. The challenge of vancomycin-resistant enterococci: A clinical and epidemiologic study
5. Stool carriage, clinical isolation, and mortality during an outbreak of vancomycin-resistant enterococci in hospitalised medical and/or surgical patients
6. The emergence of Enterococcus faecium resistant to glycopeptides and other standard agents - A preliminary report
7. Controlling vancomycin-resistant enterococci
8. Vancomycin-resistant Enterococcus faecium sepsis following persistent colonization
9. A cluster of vancomycin-resistant Enterococcus faecium in an intensive care unit
10. Recommendations for preventing the spread of vancomycin resistance
11. Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin
12. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: Guidelines for the prevention of antimicrobial resistance in hospitals
13. Influence of oral glycopeptides on the fecal flora of human volunteers: Selection of highly glycopeptide-resistant enterococci
14. Epidemiology and mortality risk of enterocomycin-resistant enterococcal bloodstream infections
15. Emergence of vancomycin-resistant enterococci in New York city
16. Clinical and molecular epidemiology of hospital Enterococcus faecium isolates in eastern France
17. Vancomycin control measures at a tertiary-care hospital: Impact of interventions on volume and patterns of use
18. Tables of antimicrobial agent pharmacology
19. Vancomycin use in a university medical center: Effect of a vancomycin continuation form
20. Effect of a vancomycin restriction policy on ordering practices during an outbreak of vancomycin resistant Enterococcus faecium
21. Prescribing pattern of vancomycin in a community teaching hospital with low prevalence of vancomycin-resistant enterococci
22. Evaluation of vancomycin use in a pediatric teaching hospital based on CDC criteria
23. The epidemiology of intravenous vancomycin usage in a university hospital
24. Impact of a vancomycin restriction policy on use and cost of vancomycin and incidence of vancomycin-resistant Enterococcus
25. The epidemiology of vancomycin usage at a children's hospital, 1993-1995
26. Epidemiology, appropriateness, and cost of vancomycin use
27. Enterococci and vancomycin resistance
28. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci
29. Do intensive hospital antibiotic control programs prevent the spread of antibiotic resistance?
30. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users
31. Comparative efficacy of daptomycin, vancomycin, and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role of test conditions in this determination
32. A pharmacoeconomic model to evaluate antibiotic costs